Treatment-dependent and treatment-independent risk factors associated with the risk of diabetes-related events: a retrospective analysis based on 229,042 patients with type 2 diabetes mellitus-Reference-Cited by-同舟云学术

Treatment-dependent and treatment-independent risk factors associated with the risk of diabetes-related events: a retrospective analysis based on 229,042 patients with type 2 diabetes mellitus

Published:2015 Issue:1 Volume:14 Page:14
ISSN:1475-2840
Container-title:Cardiovascular Diabetology
language:en
Short-container-title:Cardiovasc Diabetol

Author:

Wilke Thomas,Mueller Sabrina,Groth Antje,Fuchs Andreas,Seitz Lisa,Kienhöfer Joachim,Maywald Ulf,Lundershausen Rainer,Wehling Martin

Publisher

Springer Science and Business Media LLC

Subject

Cardiology and Cardiovascular Medicine,Endocrinology, Diabetes and Metabolism

Link

http://link.springer.com/article/10.1186/s12933-015-0179-2/fulltext.html

Reference34 articles.

1. Kosten des Typ-2-Diabetes in Deutschland

2. Changes in short- and long-term cardiovascular risk of incident diabetes and incident myocardial infarction—a nationwide study

3. Global Guideline for Type 2 Diabetes

4. High-Normal HbA1c Is a Strong Predictor of Type 2 Diabetes in the General Population

5. Current controversies in the use of haemoglobin A1c

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Primary care monitoring of HbA1c tests in type 2 diabetic patients in Northern France and impact of the successive COVID-19 pandemic containments;Diabetes Epidemiology and Management;2024-10

2. Severity of Complications and Duration of Type 2 Diabetes and the Risk of Cancer: A Population-Based Study;Cancer Epidemiology, Biomarkers & Prevention;2024-02-27

3. Adapted Diabetes Complications Severity Index and Charlson Comorbidity Index in predicting all-cause and cause-specific mortality among patients with type 2 diabetes;BMJ Open Diabetes Research & Care;2023-03

4. Molecular Bioactivity Prediction of HDAC1: Based on Deep Neural Nets;Springer Proceedings in Business and Economics;2022

5. Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis;Leukemia;2021-01-07